Skip to main content
SK Biotek to acquire BMS' API facility in Ireland

Seoul, South Korea-based SK Biotek will acquire Bristol-Myers Squibb's active pharmaceutical ingredient manufacturing facility in Swords, Ireland, under a deal that is anticipated to close by the fourth quarter of the year. SK Biotek will manufacture the facility's current portfolio, including BMS' and Pfizer's Eliquis, or apixaban.

Full Story: